LDHA mRNA Inhibitors
1 drugsAbout LDHA mRNA
LDHA mRNA encodes for the LDHA enzyme, a crucial component of anaerobic glycolysis that generates energy in the absence of oxygen. It plays a key role in cellular metabolism.
While there is currently no genetic evidence directly linking LDHA mRNA to specific diseases, its role in cellular metabolism makes it a target of interest. LDHA mRNA is a target of interest, particularly in therapeutic areas where metabolic dysregulation is a key factor.
There is one FDA-approved drug, RIVFLOZA, that targets LDHA mRNA. RIVFLOZA, developed by Novo Nordisk, is an siRNA therapeutic approved in 2023.
Top LDHA mRNA Drugs
Novo Nordisk is the only company with an approved drug targeting LDHA mRNA.
The lack of competitors suggests a high barrier to entry or an untapped market opportunity.
LDHA mRNA Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets LDHA mRNA, using sirna modality.
Explore alternative modalities to diversify the therapeutic approach and potentially overcome limitations of siRNA delivery.
LDHA mRNA Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on LDHA mRNA. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
LDHA mRNA Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval was RIVFLOZA in 2023.
The recent approval suggests a growing interest in LDHA mRNA as a therapeutic target, but market saturation is low.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on LDHA mRNA. A trial counts if an approved drug acting on LDHA mRNA is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.